Chuang, H.-Y.; Su, Y.-k.; Liu, H.-W.; Chen, C.-H.; Chiu, S.-C.; Cho, D.-Y.; Lin, S.-Z.; Chen, Y.-S.; Lin, C.-M.
Preclinical Evidence of STAT3 Inhibitor Pacritinib Overcoming Temozolomide Resistance via Downregulating miR-21-Enriched Exosomes from M2 Glioblastoma-Associated Macrophages. J. Clin. Med. 2019, 8, 959.
https://doi.org/10.3390/jcm8070959
AMA Style
Chuang H-Y, Su Y-k, Liu H-W, Chen C-H, Chiu S-C, Cho D-Y, Lin S-Z, Chen Y-S, Lin C-M.
Preclinical Evidence of STAT3 Inhibitor Pacritinib Overcoming Temozolomide Resistance via Downregulating miR-21-Enriched Exosomes from M2 Glioblastoma-Associated Macrophages. Journal of Clinical Medicine. 2019; 8(7):959.
https://doi.org/10.3390/jcm8070959
Chicago/Turabian Style
Chuang, Hao-Yu, Yu-kai Su, Heng-Wei Liu, Chao-Hsuan Chen, Shao-Chih Chiu, Der-Yang Cho, Shinn-Zong Lin, Yueh-Sheng Chen, and Chien-Min Lin.
2019. "Preclinical Evidence of STAT3 Inhibitor Pacritinib Overcoming Temozolomide Resistance via Downregulating miR-21-Enriched Exosomes from M2 Glioblastoma-Associated Macrophages" Journal of Clinical Medicine 8, no. 7: 959.
https://doi.org/10.3390/jcm8070959
APA Style
Chuang, H.-Y., Su, Y.-k., Liu, H.-W., Chen, C.-H., Chiu, S.-C., Cho, D.-Y., Lin, S.-Z., Chen, Y.-S., & Lin, C.-M.
(2019). Preclinical Evidence of STAT3 Inhibitor Pacritinib Overcoming Temozolomide Resistance via Downregulating miR-21-Enriched Exosomes from M2 Glioblastoma-Associated Macrophages. Journal of Clinical Medicine, 8(7), 959.
https://doi.org/10.3390/jcm8070959